Notable
ARO-DIMERPA · Mixed Hyperlipidemia
Primary completion pushed from Sep 30, 2026 to Jul 2027
Arrowhead PharmaceuticalsPhase 1/2 NCT07223658 Registry history of NCT07223658 on ClinicalTrials.gov (opens the registry)
8 trials changed in the last 30 days: 0 stopped, 2 with notable changes, 6 with minor changes only.
Primary completion pushed from Sep 30, 2026 to Jul 2027
Arrowhead PharmaceuticalsPhase 1/2 NCT07223658 Registry history of NCT07223658 on ClinicalTrials.gov (opens the registry)
Recruitment opened
And 1 more change in the last 30 days
Arrowhead PharmaceuticalsPhase 3 NCT07473843 Registry history of NCT07473843 on ClinicalTrials.gov (opens the registry)
Trial completed
Arrowhead PharmaceuticalsPhase 3 NCT06347016 Registry history of NCT06347016 on ClinicalTrials.gov (opens the registry)
Trial completed
Arrowhead PharmaceuticalsPhase 3 NCT06347003 Registry history of NCT06347003 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Final enrollment: 710 participants (planned 869)
Arrowhead PharmaceuticalsPhase 3 NCT06822790 Registry history of NCT06822790 on ClinicalTrials.gov (opens the registry)
Trial completed
Arrowhead PharmaceuticalsPhase 3 NCT06347133 Registry history of NCT06347133 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 121 → 140 locations
Arrowhead PharmaceuticalsPhase 3 NCT06880770 Registry history of NCT06880770 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 7 → 15 locations
Arrowhead PharmaceuticalsPhase 1/2 NCT06700538 Registry history of NCT06700538 on ClinicalTrials.gov (opens the registry)
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-10-06 | NCT07859813 A Trial to Evaluate the Efficacy and Safety of ARO-INHBE in Adults With Metabolic… | Phase 2 | Not Yet Recruiting |
| Phase 1 | 2 | |
| Phase 1/2 | 4 | |
| Phase 2 | 2 | |
| Phase 3 | 4 |
Obesity (2) · Alzheimer's Disease (1) · Asthma (1) · Dementia (1) · Diabetes (1) · NASH / MASH (1) · Type 2 Diabetes (1)